OXYGENE

Live / Registered — Registered (as of 02 Nov 2021)

What this means for you

Registered since 02 Nov 2021. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (the §71 affidavit of use is due by 02 Nov 2027, and its filing window is open now).

Record

Serial number
79280749
Registration number
6541534
Mark type
Word mark
Filed
15 Jan 2020
Published for opposition
17 Aug 2021
Registered
02 Nov 2021
Next maintenance filing
§71 affidavit of use, due by 02 Nov 2027 (grace period to 02 May 2028)
Attorney of record
Monte L. Falcoff/Jessica S. Sachs

Goods and services

  • Class 040 — Treatment of materials: Supply in the nature of custom manufacture of production units for biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; contract manufacturing for others of biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; production in the nature of custom manufacture of biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; none of the foregoing in the field of cancer research or for cancer therapies or vascular targeting agents
  • Class 042 — Scientific and technological services: Study in the nature of conducting scientific feasibility studies and design of production factories and buildings; inspection of production factories and buildings for quality control and consultancy purposes; engineering; preparation of technical studies; quality control of production units in the pharmaceutical and biopharmaceutical field with a view to certification; research and development of new products for third parties; technological services regarding manufacture of biological molecules, particularly viral vectors and monoclonal antibodies, in the pharmaceutical and biopharmaceutical field; none of the foregoing in the field of cancer research or for cancer therapies or vascular targeting agents

Owner

Board proceedings on this mark

The owner also pleads this mark in 1 other Board proceeding.

Prosecution history

  • 03 Nov 2026 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
  • 20 Aug 2026 — NEW REPRESENTATIVE AT IB RECEIVED
  • 04 May 2024 — NEW REPRESENTATIVE AT IB RECEIVED
  • 15 May 2022 — FINAL DECISION TRANSACTION PROCESSED BY IB
  • 21 Apr 2022 — FINAL DISPOSITION NOTICE SENT TO IB
  • 21 Apr 2022 — FINAL DISPOSITION PROCESSED
  • 02 Feb 2022 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
  • 02 Nov 2021 — REGISTERED-PRINCIPAL REGISTER
  • 23 Aug 2021 — ASSIGNED TO EXAMINER
  • 17 Aug 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 17 Aug 2021 — PUBLISHED FOR OPPOSITION
  • 14 Aug 2021 — NOTIFICATION PROCESSED BY IB
  • 28 Jul 2021 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
  • 28 Jul 2021 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
  • 28 Jul 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

View this trademark record on Rightsy